natgillin/translations-raw huggingface dataset:
That: a. the European Commission follows closely relevant activities anddevelopments of the Member States in this field and in the global context;b. action be taken at the EU level, in coordination with other initiatives, tofollow and address regulatory issues related to collections of humanbiological material and associated data and their uses.
Da naj: a. Evropska komisija skrbno spremlja ustrezne dejavnosti in razvoj drÏav ãlanic na tem podroãju in v svetovnem okviru;b. se na ravni EU sprejme ukrep v sodelovanju z drugimi pobudami za spremljanje in re‰evanje zakonodajnih vpra‰anj, povezanih z zbirkami ãlove‰kega biolo‰kegamateriala in z njimi povezanih podatkov ter njihovo uporabo.
Cross-border exchange of samples and data is important to improve European co-operation inthis field.
22. âezmejna izmenjava vzorcev âezmejna izmenjava vzorcev in podatkov je pomembna za izbolj‰anje evropskega sodelovanjana tem podroãju.
Ethical questions, such as validity of informed consent, play an important role in thistransfer.
Pri tem prenosu imajo pomembno vlogo etiãna vpra‰anja, kot je veljavnostobve‰ãenega soglasja.
See report, chapter 1.4.
Glej poroãilo, poglavje 1.4.
Recommendation 22
Priporoãilo 22
That: a. the European Commission evaluates the need for, and the feasibility of,developing harmonised standards for the research use of human samplesand associated data (including informed consent issues), taking intoaccount relevant international conventions on cross-border exchange ofsamples.
Da naj: a. Evropska komisija ovrednoti potrebo po razvoju in izvedljivost usklajenihstandardov za raziskovalno uporabo ãlove‰kih vzorcev in povezanih podatkov(vkljuãno z vpra‰anji obve‰ãenega soglasja) ter pri tem upo‰teva ustreznemednarodne konvencije o ãezmejni izmenjavi vzorcev.
Consent issues for samples from individuals and groups entering new collections may differ fromthose applicable to existing collections, where contact may not have been maintained with thesource individuals over the years. Explicit written consent is the rule but may not always be feasiblefor future uses of the samples and/or data not envisaged at the time of collection.
Vpra‰anja o soglasju posameznikov in skupin, ki se vkljuãujejo v nove zbirke, se lahko razlikujejood vpra‰anj, ki se nana‰ajo na obstojeãe zbirke, kjer stik z dajalci ãez leta morda ni bil ohranjen.Pravilo je jasno pisno soglasje, ki ga pa ni vedno mogoãe doseãi za prihodnje uporabe vzorcevin/ali podatkov, ki jih ob ãasu zbiranja ‰e nismo predvideli.
The issuesat stake include respect for individual or community autonomy regarding their control over theuse of samples, the distribution and flow of data and samples across national borders, and methodsthat are both compatible with the nature of the research yet respect human rights.
Ta vpra‰anja vkljuãujejo upo‰tevanjeposameznikove avtonomnosti ali avtonomije skupnosti glede njegovega ali njenega nadzora naduporabo vzorcev, razporejanjem in pretokom podatkov in vzorcev ãez drÏavne meje, metodami,ki so usklajene z naravo raziskovanja, vseeno pa upo‰tevajo ãlovekove pravice. V EU obstajajorazliãna stali‰ãa in prakse.
Professionals working in human genetics have developedrecommendations and several ethical bodies have taken positions.
Strokovnjaki, ki delujejo na podroãju ãlove‰ke genetike, so razvilipriporoãila, ‰tevilni etiãni organi pa so zavzeli stali‰ãa.
Genetic data represent personal information which may or may not have individual medicalrelevance, as well as medical or cultural relevance at the community level.
Genski podatki so osebni podatki, ki lahko imajo medicinski pomen za posameznika, lahko pa tudi ne, na ravni skupnosti pa lahko imajo zdravstveni ali kulturni pomen.
Biological samplesand associated or derived genetic or medical information of any kind and of any origin mustnot be collected, stored or used without obtaining informed consent based on adequateprocess and procedure, including appropriate approval by relevant review bodies, and considerationof community-related aspects where appropriate, regardless of the purpose of the collectionand the level of anonymity.
Biolo‰kih vzorcev in povezanih ali iz njih pridobljenih genskih ali zdravstvenih podatkov kakr‰nekoli vrste ali izvorane smemo zbirati, hraniti ali uporabljati brez pridobljenega obve‰ãenega soglasja na podlagiustreznega procesa in postopka, vkljuãno z ustrezno odobritvijo ustreznih pregledovalnihorganov, ter po potrebi upo‰tevanjem vidikov, povezanih s skupnostjo, ne glede na namenzbiranja in stopnje zagotavljanja anonimnosti.
Samples for genetic diversity studies should only be obtained incompliance with local or national ‘traditions’ and regulations or laws.
Vzorce za ‰tudije genske razliãnosti se smepridobivati samo v skladu z lokalnimi ali narodnimi "tradicijami" ter predpisi ali zakoni.
The sources of samplesand individual data and the relevant agreement regarding their use should be documented inall protocols and publications.
Virevzorcev in podatkov posameznikov ter ustrezne dogovore glede njihove uporabe je treba zabeleÏiti v vseh protokolih in objavah.
The informed consent process and procedures used should befully transparent with regard to the planned research, including policies on provision of test resultsto individuals and to the population, as well as to the handling of samples and to the rights ofsample donors.
Uporabljeni proces in postopki obve‰ãenega soglasjamorajo biti popolnoma transparentni glede naãrtovanega raziskovanja, vkljuãno z naãeli dajanjaizsledkov testov posameznikom in prebivalstvu, pa tudi glede ravnanja z vzorci in pravicamidajalcev vzorcev.
The Group considers that views of both patients and patient organisations, andpublic debate about biobanks, in particular with regard to consent issues, should be exploredfurther.
Skupina je mnenja, da je treba globlje raziskati stali‰ãa bolnikov in organizacijbolnikov ter javnih razprav o biolo‰kih bankah, zlasti glede vpra‰anj o soglasjih.
See report, chapters 3.3.2, 4.1 and 7.1.4.
Glej poroãilo,poglavja 3.3.2, 4.1, 5.1.2 in 7.1.4.
Recommendation 23
Priporoãilo 23
GENETIC TESTING AS A RESEARCH TOOL
GENSKO TESTIRANJE KOT RAZISKOVALNA METODA
As regards samples and genetic data from the deceased, the Group considers that in the caseof the overriding interest of one or more blood relatives, even in the absence of consent givenbefore death, their use could be legitimate: absence of consent should not be considered asequivalent to non-consent.
Glede vzorcev in genskih podatkov umrlih Skupina meni, da je v primeru prevladujoãega interesaenega ali veã krvnih sorodnikov, tudi brez podanega soglasja pred smrtjo, njihova uporaba lahkozakonita: odsotnosti soglasja ne smemo imeti za enako nestrinjanju.
Furthermore, their use should be permitted, when made anonymous,for research, development of genetic tests, and for teaching purposes. See report, chapter 4.1.
Poleg tega je treba njihovoanonimno uporabo dovoliti za raziskovanje, razvoj genskih testov in v izobraÏevalne namene.Glej poroãilo, poglavje 4.1.
Recommendation 24
Priporoãilo 24
That: a. the use of tissue and accompanying data from minors or vulnerableindividuals in research be permitted if, in so doing, their interests areserved; b. specific consideration be given to children’s views, the information providedto them, and issues of children’s assent and/or consent.
Glede sodelovanja otrok ali ranljivih oseb v genskih ‰tudijah velja naãelo delovanja v njihovemnajbolj‰em interesu, pravilo pa je posebna za‰ãita, kot to velja za katere koli raziskave pri ljudeh.Pomembno vpra‰anje, ki je posledica dolgotrajnega hranjenja in uporabe podatkov in vzorcev,pridobljenih od otrok, je povezano z vpra‰anjem, kdaj je treba pridobiti privolitev oziromasoglasje.
European Commission EUR 21120 – 25 recommendations on the ethical, legal and social implications of genetic testing Luxembourg: Office for Official Publications of the European Communities2004 – 25 pp. – 17,6 x 25 cm ISBN 92-894-7308-8
Evropska komisija EUR 21120 – 25 priporoãil o etiãnih, pravnih in druÏbenih implikacijah genskega testiranja Luxembourg: Urad za uradne objave Evropskih skupnosti2004 – 25 str. – 17,6 X 25 cm ISBN 92-894-7322-3
The how and the why:
Evropske raziskave v akciji
• European Research Area:http://europa.eu.int/comm/research/era/index_en.html
• Evropski raziskovalni prostor:http://europa.eu.int/comm/research/era/index_en.html
ERA has been described by the Commission as “pivotal to securing Europe’s economic andcompetitive future”.
Evropska komisija je prostor ERA opisala kot “kljuãni dejavnik za zagotovitev gospodarskeinkonkurenãne prihodnosti Evrope”.
Putting it into practice is not an option but a necessary ingredient for sustaining Europe’s much-envied quality of life. FP6 is the most important tool for bringing ERA to life.
Uresniãevanje ERA ni samo ena od moÏnosti, temveã potrebenelement, ki ohranja pogosto zavidano evropsko kakovost Ïivljenja. ·esti. okvirni program jenajpomembnej‰e orodje za oÏivitev ERA.
Thismeans stimulating innovation and improving the use and transfer of research results into commercialtechnologies in the Union and all its regions, including the new Member States.
To pomeni, da je treba spodbujati inovacije in izbolj‰atiuporabo in prenos rezultatov raziskav v komercialne tehnologije, tako znotraj Unije kot v vse njeneregije, skupaj z novimi drÏavami ãlanicami.
• Towards 3% of GDP:http://europa.eu.int/comm/research/era/3pct/index_en.html
• Evropski raziskovalni prostor je postal stvarnost:
What comes next for European research excellence?
Bodoãe perspektive EU na raziskovalnem podroãju Kaj ãaka odliãnost evropskih raziskav?
• Making a reality of the European Research Area: Guidelines for EU Research Activities: http://europa.eu.int/eur-lex/en/com/cnc/2000/com2000_0612en01.pdf
Smernice za raziskovalne dejavnosti v EU: http://europa.eu.int/eur-lex/en/com/cnc/2000/com2000_0612en01.pdf
With modern premises and up-to-date equipment, the VUJETrnavacompany is a high-techstrategic gem in present-day Slovakia.
Z modernimi objekti in sodobnotehnologijo velja podjetje VUJETrnavadanes na Slova‰kemzazelo razvit tehnolo‰ko-strate‰kibiser.
On 16 June 2004, the Commission adopted a Communication, entitled Science and technology:the key to Europe’s future, aimed at securing Europe’s leading role in research and technologicaldevelopment. This Communication, based on a February 2004 EU financial proposal, recommendsdoubling the budget devoted to European research to around 10 billion a year from 2007-2013, aperiod that will include the Seventh Framework Programme.
Komisija je 16. junija 2004 izdala poroãilo z naslovom Znanost in tehnologija - kljuã v prihodnost Evrope, ki naj bi zagotovilo vodilno vlogo Evrope na podroãju raziskav in tehnolo‰kega razvoja.Toporoãilo, ki temelji na finanãnem predlogu EU od februarja 2004, priporoãa podvojitev sredstev,kiso namenjena evropskemu raziskovanju, in sicer na pribliÏno 10 milijard letno v obdobju 2007-2013,se pravi v obdobju, v katerem bo zaobseÏen 7. okvirni program.
THE EUROPEANRESEARCH AREA(ERA)
EVROPSKIRAZISKOVALNIPROSTOR (ERA)
The main reason for this increase is to make it possible to exploit fully the added value of EU-wideaction by creating critical masses of material, human and intellectual resources, and by exerting apowerful leverage effect on private investment in research.
Glavni razlog za to poveãanje je, da bi se z ustvarjanjem kritiãnih mas materiala, ãlove‰kihinintelektualnih virov ter z izvajanjem moãnega uãinka vzvoda na zasebne naloÏbe v raziskave,omogoãil polni izkoristek dodane vrednosti vseevropske akcije.
• Key Figures 2003-2004 (Towards an ERA: Science, Technologyand Innovation):http://europa.eu.int/comm/research/era/keyfigures_en.html
(K ERA: Znanost, tehnologije in inovacije): http://europa.eu.int/comm/research/era/keyfigures_en.html
The Communication presents six major objectives to stimulate competitive R & D in the Union,including the creation of European centres of excellence, the launching of technology initiatives ingrowing industrial fields, and the creation of a European Agency to support European basic researchteams.
V dokumentu je podanih ‰est kljuãnih ciljev za spodbujanje konkurenãne R & R v Uniji, skupajzustanovitvijo evropskih centrov odliãnosti, oÏivljanjem tehnolo‰kih pobud v industrijske panogevrazvoju ter z ustanovitvijo evropske agencije za podporo evropskim temeljnim raziskovalnimskupinam.
It endorses further effort being put into developing R & D infrastructures and boosting thenumbers of skilled researchers in key sectors.
Z razvojem infrastruktur R & R in s poveãanjem ‰tevila usposobljenih raziskovalcevvkljuãnesektorje dokument podpira nadaljnja prizadevanja.
• Investing in Research: an Action Plan for Europe (PDF):http://europa.eu.int/comm/research/era/3pct/pdf/action-plan.pdf
• NaloÏbe v raziskave: Akcijski naãrt za Evropo (PDF):http://europa.eu.int/comm/research/era/3pct/pdf/action-plan.pdf
Evolution of EU Research Framework Programme Budgets
Evolucija proraãunov okvirnihprogramov EU za raziskave
It is also intended to focus future European researchefforts on key topics.
Sodelovanje za bolj‰o
This publication was produced by:European Commission Research Directorate-General E-mail: research@cec.eu.inthttp://europa.eu.int/comm/research
Namenjen je tudi temu, da bi se prihodnji evropskiraziskovalni napori osredotoãali na kljuãne teme.Opredeljeni sta dve novi podroãji: vesolje in varnost.Glede znanosti in tehnologije pa omenjeni dokumentpriporoãa, da se raziskave na teh podroãjih podprejozuãinkovitej‰im izvajanjem, na primer z upravljanjemspomoãjo javno-zasebnega partnerstva.
European Commission Directorate-General for Research July 2004
Evropska komisija Generalni direktorat Raziskave Julij 2004 prihodnost v raz‰irjeni
Information and Communication Unit Fax: +32 2 295 82 20B-1049 Brussels
SluÏba za informacije in komunikacije Faks: +32 2 295 82 20B-1049 Bruselj
Shaping ERA
Oblikovanje ERA
Context and challenges:
Dejstva in podatki
Framework Programmes for research:
Okvirni programi za raziskave: ·esti okvirni program
Facts and figures:Europe vs Japan and the USA
Zakaj Evropska unija podpira raziskovalno dejavnost?
FP6 projectsfunded with thenew instruments:
Projekti 6.okvirnegaprograma,financiraniznovimiinstrumenti:
Since the launch of the First Framework Programme for RTD, in 1984,the Union has played a leading role in setting up and implementingmultidisciplinary research and co-operative activities in Europe andbeyond (see Budgets graph).
Odkar je bil leta 1984 zastavljen Prvi okvirni program za raziskaveintehnolo‰ki razvoj, igra Unija vodilno vlogo pri vzpostavljanju in izvajanjumultidisciplinarnih raziskovalnih dejavnosti in dejavnosti sodelovanja v Evropi in ‰ir‰e (glej proraãunski diagram).
The EU’s Research programmes were thefirst to include the new Member States in collaborative projects.
Raziskovalni programi EU so biliprvi, s katerimi so nove drÏave ãlanice sodelovale v projektih sodelovanja.
The European Research Area was conceived toincrease the coherence and impact of Europeanresearch.
Evropski raziskovalni prostor je bil spoãetznamenom, da se izbolj‰a sovisnost in vplivnostevropskih raziskav.
In its founding document, Towards a European Research Area, it cites severalconcrete challenges it aims to meet.
V ustanovitvenemdokumentu z naslovom Skupni evropskiraziskovalni prostor, je navedenih nekajkonkretno zastavljenih izzivov, ki jih Ïeliuresniãiti.
Picture this scenario: a team of scientists in Lisbon makes a breakthrough incytogenetics, unlocking the vital clues to hereditary cancer.
Predstavljajte si takle scenarij: skupina znanstvenikov v Lizboni razre‰iuganko glede rakavih obolenj, s ãimer ji uspe pomembno odkritjenapodroãju citogenetike.
They spendsignificant time and money verifying their findings only to be told that a Swedish team reached virtually the same conclusion just two months earlier.
Porabili so veliko ãasa in denarja za preverjanjeizsledkov, nato pa zvedeli, da je pred dvema mesecema ‰vedska skupinapri‰la do tako rekoã enakega sklepa.
One way of measuring progress towards becoming theworld’s standard-bearer of innovation and science is tocompare the EU with its main competitors, the USA and Japan.
Eden izmed naãinov, kako merimo napredek na potiksvetovnemu nosilcu standarda na podroãju inovacijin znanosti, je primerjava EU z njenima glavnimakonkurentoma - ZDA in Japonsko.
The 2003 European Innovation Scoreboard – a benchmarking tool – shows on almost all measuresthat the Union’s innovation performance (see Usefullinks) remains weaker than the USA’s, despite the Lisbonand Barcelona strategies.
Evropska lestvica doseÏkov 2003 - orodje za merjenje uspe‰nosti, kaÏe na skoraj vseh merilih, da je inovacijskauãinkovitost Unije (glejte poglavje Koristne povezave)kljub strategijam, ki so bile doloãene v Lizboni in Barceloni, ‰e vedno ‰ibkej‰a od ameri‰ke.
The Sixth Framework Programme (FP6) 2002-2006 concentrates onhigh-quality research which both focuses and integrates Europe’s science and research.
·esti okvirni program (OP6) 2002-2006 se osredotoãa na zelokakovostno raziskovalno dejavnost, ki evropski znanosti in raziskavamnamenja vso pozornost in jih hkrati povezuje.
It is also striving to make the most of transnationalco-operation, progressively integrating activities and actors so that Europe may concentrate on fewer thematic research priorities.
Obenem teÏi k ãimveãji uãinkovitosti transnacionalnega sodelovanja, in postopoma zdruÏuje dejavnosti in akterje, s ãimer naj bi se Evropa osredotoãala namanj tematskih raziskovalnih prednostnih nalog.
When the European Union laments the fragmentation of Europeanresearch, this is partly what it is referring to.
Prav na tak‰nih izku‰njah delno temelji obÏalovanje Evropske unije glederazdrobljenosti evropske raziskovalne dejavnosti.
Helping research stakeholderscommunicate more efficiently and improving the way they coordinate theiractivities across Europe are major EU objectives.
Kljuãna cilja Evropskeunije sta zato, pomoã interesnim skupinam pri bolj uãinkovitemkomuniciranju in izbolj‰anje naãinov za uskladitev njihovih dejavnostiznotraj evropskega prostora.
These include better use of scientific resourcesand facilities at the European level, moredynamic private investment in R & D, increasedhuman resources and researcher mobility, aswell as providing conditions more conducive fora research area of ‘shared values’.
Sem spadajo: smotrnej‰e izkori‰ãanjeznanstvenih virov in infrastrukture na evropskiravni, veãja dinamiãnost zasebnih naloÏb v R & R, veã kadrov in bolj‰a mobilnostraziskovalcev, kakor tudi zagotovitev ugodnej‰ihpogojev za raziskovalno podroãje ‘skupnihvrednot’.
Sum of (sm)all parts
Se‰tevek vseh (malih) prispevkov
In the same year that ERA wasborn, Europe’s leaders cameup with the Lisbon Strategyat the European Summit in Portugal.
Isto leto, kot je bilo zabeleÏeno rojstvo ERA,seje evropskim voditeljemna evropskem vrhu na Portugalskem porodilazamisel o tako imenovanilizbonski strategiji.Strategija se osredotoãanaukrepe, ki bi omogoãili,da bi Evropa do leta 2010postala “najbolj dinamiãnoinkonkurenãnogospodarstvo znanjanasvetu”.
The strategy focusedon helping Europe become the“most dynamic andcompetitive knowledge-basedeconomy in the world by2010”.
To strategijosodve leti pozneje, na vrhuv Barceloni, okrepili s cilji,skaterimi bi spodbujali drÏave ãlanice k poveãanjuodstotka BDP-ja, ki jenamenjen raziskavaminrazvoju.
Two years later, at the Barcelona Summit, sensing the EU was falling behindschedule, this strategy wasreinforced with targetsencouraging Member States toincrease the percentage of GDP they spend on researchand development – the socalled 3% Objective.
Ta pobudajedobila ime Cilj 3%.
A summary review of the inventions and scientific discoveries whichchanged the world, such as television and the Web, reveals Europe’s long-standing tradition of excellence in research and innovation.
• nanotehnologije in nanoznanosti, na znanju temeljeãi, veãnamenskimateriali ter novi proizvodni postopki in naprave (1.30 milijarde EUR);
At its core, ERA aims to pool dispersed resourcesand expertise so that important and rewardingprojects can be undertaken. Through improvedinformation exchange and coordination, the aimis to help cut back on red tape – increasingefficiency and confidence in the process.
Kratek pregled izumov in znanstvenih odkritij, ki so spremenila svet,kotstana primer televizija in splet, razkrije dolgoletno evropsko izroãiloodliãnosti na podroãju raziskav in inovacij.
Broadly speaking, the seven main thematic priorities for FP6 to focusand integrate research are:• Life sciences: genomics and biotechnology for health (2.25 billion)• Information society technologies (3.62 billion)• Nanotechnologies and nanosciences, knowledge-based multifunctionalmaterials and new production processes and devices (1.30 billion)• Aeronautics and space (1.07 billion)• Food quality and safety (685 million)• Sustainable development, global change and ecosystems (2.12 billion)• Citizens and governance in a knowledge-based society (225 million)
• aeronavtika in vesolje (1.07 milijarde EUR);• kakovost in varnost Ïivil (685 milijonov EUR);
One of the main tools for measuring this performance ishow much a country spends on R & D as a percentage ofits GDP.
Eno izmed glavnih orodij s katerim merimo touãinkovitost je, koliko neka drÏava potro‰i za R & R,insicer v odstotkih svojega BDP-ja.
The Barcelona 3% Objective is a threshold ofresearch spending that Member States should reach inorder to keep the Union on target to becoming theworld’s most dynamic knowledge-based economy.Overall, the EU-15 has managed to increase marginallythe amount it spends on R & D from 1.92% in 1999 to1.99% in 2002.
Cilj 3%, ki je bilzastavljen v Barceloni, je prag porabe za raziskovalnodejavnost, ki bi ga drÏava ãlanica morala doseãi, da bi Unija lahko ostala pri svojem cilju, da pridobinaslov "najbolj dinamiãno gospodarstvo znanja nasvetu". Evropski uniji petnajsterice je komaj uspelopoveãati zneske, ki jih namenja R & R, z 1,92% leta1999 na 1,99% leta 2002.
But, on average, the Union still lagsbehind its main competitors, Japan (2.98%) and the USA (2.80%).
Toda na splo‰no Unija‰evedno zaostaja za svojima glavnima konkurentoma Japonsko (2,98%) in ZDA (2,80%).
See graph for details.
Natanãni podatkiso prikazani v diagramu.
SEAFOODplus This Integrated Project waslaunched in early 2004 andfocuses on reducing healthproblems and diseasesassociated with seafood/fishfarming and production.
Cilj ERA je, da bi zdruÏil razpr‰ene vire terstrokovno znanje in izku‰nje, nato pa bi se lahkolotili ‰e pomembnej‰ih in ‰e koristnej‰ihprojektov.
Among the 70 partnersfrom 16 European countries,including new Member States,are representatives fromindustry, academia andcommerce – especially SMEs.
Z uãinkovitej‰o izmenjavo informacijin usklajevanjem Ïeli zmanj‰ati birokratskisistem ter tako doseãi veãjo uãinkovitostinzaupanje v proces.
While it continues to lead the way in many fields of science and technology– notably in energy and medical breakthroughs – Europe’s skilled scientistsand centres of expertise have tended to be scattered across the continent.Just as the scenario above shows, the Union’s research efforts suffer in theabsence of adequate networking and co-operation.
Loteva se tem,kot je etika ribogojstva, izzivovzapotro‰nika in okolje, kakortudinaãinov zaizbolj‰anjeproizvodnje in smotrnej‰euporabe stranskih proizvodov.Prispevek EU za ta projektje55% sredstev celotnegazneska 26 milijonov EUR.Med70 partnerji iz 16 evropskih drÏav, skupaj z novimi drÏavami ãlanicami, so predstavnikiindustrije, akademskega svetaintrgovine, zlasti malih in srednjevelikih podjetij.
An important feature of FP6 was the creation of new fundinginstruments – such as the Networks of Excellenceand Integrated Projects – to assemble a critical mass of expertise and resources toachieve ambitious research objectives.
• drÏavljani in upravljanje v druÏbi znanja (225 milijonov EUR).
Big budget, great opportunities
GA âlove‰ki viri so kljuãnidejavnik
To breathe life into ERA, the Commissionpublished a document entitled Making areality of ERA: Guidelines for EU Research Activities, which also helped shape the Sixth Framework Programme for research.
Tako kot je ilustriral omenjeniscenarij, zaradi pomanjkanja ustreznega povezovanja v omreÏja in sodelovanja, trpijo raziskovalni napori Unije.